WIN $5,000 IN THE BIOHEALTH CAPITAL REGION LOGO COMPETITION
DEADLINE EXTENDED TO JUNE 20
The biohealth industry in Maryland, Virginia and DC needs a strong identity and brand that will help it grow and attract the best talent in the world. We have a new name, tagline and wordmark…
…but we need an icon that captures the spirit of the industry and the region.
Anyone from an organization (college, company, PR firm, etc.) based in Maryland, Virginia or DC may submit an entry.
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the peer-reviewed journal, Science Translational Medicine, has published preclinical research in its May 25 issue pointing to a potential clinical application for GMI-1271 in the treatment of breast cancer. The published study details research in an in vivo model that showed the company’s drug candidate, GMI-1271, a novel E-selectin antagonist, inhibits breast cancer metastasis.
Vtesse, Inc. announced today that the dose-finding portion of the company’s global, pivotal Phase 2b/3 clinical trial for its lead investigational product, VTS-270, for treatment of Niemann-Pick Type C1 Disease (NPC) is now complete, and a dose level for further testing has been selected by an independent dose selection committee (DSC). Vtesse’s ongoing Phase 2b/3 prospective, randomized, double-blind, sham-controlled trial is a three-part, efficacy and safety trial of VTS-270, administered by the lumbar intrathecal (IT) route every two weeks. VTS-270 is based on a specific, well-characterized composition of 2-hydroxypropyl-beta-cyclodextrin.
Novavax Inc. has won a potentially lucrative fast-track designation from the U.S. Food and Drug Administration for one of its lead vaccine candidates to protect older patients against a respiratory virus known as RSV.
Senseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced it has signed an exclusive distribution agreement with Roche for the multi-country commercialization of Senseonics’ Eversense® Continuous Glucose Monitoring System.
Pharma major Lupin today said it has received an establishment inspection report (EIR) from the USFDA on closure of inspection of its Mandideep and Aurangabad facilities.
In a BSE filing, Lupin said: “It has received establishment inspection report (EIR) for its Mandideep and Aurangabad facilities wherein the USFDA has concluded that the inspections stand closed.”
From Stewart Edelstein, Executive Director, Universities at Shady Grove:
“I am pleased to announce the appointment of Ms. Richee L. Smith Andrews as USG’s first Chief Development Officer. Richee brings over 15 years of development experience and will lead USG’s efforts to secure development funding, endowments, and major gifts to support academic programing, scholarships, and student success.”
Women who get a prosthetic foot after losing a leg to disease or injury have limited shoe options, but an invention by five Johns Hopkins University students may change that. The university announced Wednesday that the “Prominence” could be the first non-custom prosthetic foot to adapt to high heels up to 4 inches high.
The National Science Foundation’s I-Corps initiative is heavily influenced by the lean start-up methodology, which calls for rapid iteration of value propositions and customer segments based on formal and extensive interviews with the industry stakeholders of a technology or service. While this methodology has proven to be very successful overall, many universities have reported difficulty engaging faculty in the process because of the six-week commitment to the program.
“Twelve weeks ago, these projects were literally just ideas,” said Rana Quraishi, PhD, director of new ventures in the Office of Research and Development at the University of Maryland, Baltimore (UMB). Quraishi was welcoming students, intellectual property experts, and scientists to the final meeting of UMB’s first-ever course in developing and pitching a biotechnology business concept, called CIPP 980.
On May 23, U.S. Senator Ben Cardin (D-Maryland) convened at Johns Hopkins Hospital a scientific expert panel to discuss what to do about the Zika epidemic. Organizing the event within two business days was no small feat, as Cardin, scientific experts, health department leaders, hospital executives and industry representatives all had to quickly clear their very busy morning schedules. The attendance of television and newspaper outlets (such as the Baltimore Sun) meant that the discussion’s proceedings would be available to the public. From the very start, Cardin kept the tone very science-focused: The Zika epidemic is a public health emergency, and the issue is how best scientifically, collaboratively and expeditiously to handle this emergency.
The fifth annual U.S. News STEM Solution Conference kicked off May 18 with a half-day look at STEM education in the Baltimore region and its impact on the local economy.
Thursday, June 2, 2016 7:30 AM – 9:00 AM, Bethesda Country Club
An IPO is one of the most important events in a company’s history, and navigating the course requires an enormous amount of endurance. Choosing an investment bank, perfecting your roadshow, and meeting with investors is just the tip of the iceberg. Join Vit Vasista, Chief Financial Officer of REGENXBIO, at All the Right Moves: Planning a Successful Exit Strategy, on Thursday, June 2, from 7:30 – 9:00 a.m. Vit will share tips that were integral to REGENXBIO’s successful 2015 IPO, from pitching to trading.
IBM is partnering with the University of Maryland, Baltimore County (UMBC) to create the Accelerated Cognitive Cybersecurity Laboratory (ACCL), which will be housed within the College of Engineering and Information Technology at UMBC. The Lab will use Watson technology to improve cybersecurity.
Longtime San Franciscans may remember the Mission Bay neighborhood, located on the southern end of the city, as the home to one of the Southern Pacific Railroad Company’s railyards. Trains ran in and out of the railyard for nearly 100 years until the 1990s.
The National Institute of Standards and Technology (NIST) released a federal funding opportunity (FFO) to establish and sustain up to eight Regional Alliances and Multistakeholder Partnerships to Stimulate (RAMPS) Cybersecurity Education and Workforce Development. Through this announcement, NIST will commit up to $1.6 million for state or regional consortiums that identify cybersecurity workforce development pathways that address local workforce needs. Although lead organizations must be a nonprofit or institution of higher education, NIST encourages public-private partnerships with industry and local governments. Proposals are due July 12, 2016.
The angel investor market in 2015 had a slight increase in investment dollars and in the deal size. Total investments in 2015 were $24.6 billion, an increase of 1.9% over 2014, according to the Center for Venture Research at the University of New Hampshire. A total of 71,110 entrepreneurial ventures received angel funding in 2015, a decline of 3.1% over 2014 investments. The number of active investors in 2015 was 304,930 individuals, a decrease of 3.7% from 2014. The change in both total dollars and the number of investments resulted in a deal size for 2015 that was larger than in 2014 (an increase in deal size of 5.1% from 2014). These data, combined with the yield rates and valuations, indicate that angels were selective in their investment behavior in 2015. The decrease in valuations over the last three years indicates a continuing market correction in valuations. However, the $24.6 billion of investments is a robust amount and is close to the market high of $26.0 billion that occurred in 2007.
Startups based in California, New York, and Massachusetts account for most of the VC tech funding in the United States. However, hotbeds of innovation are being spurred by VCs across the country.
With that in mind, we used CB Insights data to analyze the most active venture capital firm by the number of investments into tech startups in each US state from 2011 to 2016 year-to-date (through 5/9/16).
OrbiMed has launched a $307 million venture capital fund five years after its inagural $202 million fund investing in biotech, diagnostic and medical device and digital health companies.
Two sets of numbers shows how far biopharma activity has progressed in Asia recently. The value of biotech venture capital funding during the first quarter zoomed to $174 million in the first quarter from $150 million in Q4 2015 and a mere $9.4 million in Q1 2015, according to Tech In Asia.
Life science venture firm 5AM Ventures has raised $285 million for fund number 5, according to data from a Form D filing with the U.S. Securities and Exchange Commission. The firm makes investments in life science startups at the seed and early stage of their development.
The National Council of Entrepreneurial Tech Transfer (NCET2) will hold its inaugural University Startups Demo Day (USDD) at the National Press Club and Congress in Washington, DC on September 20, 2016.
The USDD provides an unprecedented opportunity for corporate open innovation and venturing groups, VCs, and angels to discover, review, partner with, and fund university startups. At the same time, it raises awareness in Congress of the pivotal role that universities play in the formation of high potential startups, the creation of high value jobs across the country, and overall national competitiveness.
The USDD will showcase thirty-five (35) of the best university startups in specific technology areas. Selected by their universities, and scored by corporates, angels, and VCs, the top scoring university startups will be invited to present at the National Press Club in the first part of the day. During the second part of the day, the companies will meet and have photo ops with their senators and representatives at Congress.
On June 8th, WTCI will hold our 10th Annual Women Spanning the Globe Leadership Conference. Over the course of the day, you will be introduced to an impressive line- up of speakers and topics ranging from being an authentic leader, living your purpose to promoting and nurturing gender equality in your professional and person life.
We have designed an interactive day with time between sessions, when the audience can “Lean In”, ask questions, encourage feedback and share their perspective. We hope all attendees will leave with a fresh perspective, new ideas, best practices to implement, new friends, and the feeling that you are part of an International Professional Sisterhood.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
